MiMedx completed its acquisition of Stability Biologics, provider of human tissue products serving the surgical, spine and orthopaedic sectors. Stability Biologics will operate as a wholly-owned subsidiary of MiMedx.
MiMedx expects full-year 2016 revenues of at least $15MM generated from Stability Biologics’ processed tissue and bone product distribution/sales.
MiMedx completed its acquisition of Stability Biologics, provider of human tissue products serving the surgical, spine and orthopaedic sectors. Stability Biologics will operate as a wholly-owned subsidiary of MiMedx.
MiMedx completed its acquisition of Stability Biologics, provider of human tissue products serving the surgical, spine and orthopaedic sectors. Stability Biologics will operate as a wholly-owned subsidiary of MiMedx.
Copy to clipboard 
